Latest news articles

Added 7 days ago Drug news

Health Canada approves Cabenuva for HIV.- ViiV Healthcare

Health Canada has approved Cabenuva (cabotegravir and rilpivirine extended-release injectable suspensions), from ViiV Healthcare, the first and only once-monthly, complete...

Added 17 days ago Drug news

DISCOVER trial of Descovy shows efficacy in HIV pre-exposure prophylaxis.- Gilead Sciences

Gilead Sciences presented longer-term results from the DISCOVER trial of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets,...

Added 18 days ago Drug news

Phase III ATLAS-2M study of cabotegravir and rilpivirine meets primary endpoint at 48 weeks in HIV.- ViiV Healthcare

ViiV Healthcare has presented positive 48-week data from its global phase III ATLAS-2M study of long-acting, injectable, 2-drug regimen (2DR)...

Search all news articles for HIV infection
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Optimising anti-TNF treatment using biosimilars

Optimising anti-TNF treatment using biosimilars

Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.

Load more

Guidelines

BHIVA guidelines on the management of HIV in pregnancy and postpartum 2018 (2019 interim update)

The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of pregnant women living with HIV (human immunodeficiency virus) in the UK and their infants.

Added 5 years ago

EACS GUIDELINES Version 9.0 October 2017

EACS produces the European Guidelines for treatment of HIV-positive adults in Europe.

Added 1 year ago

BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals 2016 (2019 interim update)

As with the previous monitoring guideline, the aim is to present a consensus regarding the standard assessment and investigation of HIV infection from the time of diagnosis and to describe the appropriate monitoring of HIV-positive individuals...

Added 8 years ago

Search all guidelines for HIV infection
 

Journal articles

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.

Background: Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, and has a favorable...

Added 6 months ago

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.

Background: Doravirine is a novel, nonnucleoside reverse transcriptase inhibitor with demonstrated efficacy in treatment-naive adults with HIV-1.

Added 6 months ago

Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.

Background: The safety and efficacy of doravirine were compared with that of efavirenz as initial treatment of adults living with HIV-1 infection (NCT01632345).

Added 6 months ago

Search all journal articles for HIV infection
 

Clinical trials

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults (Alliance)

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate...

Added 8 months ago

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

The purpose of this study is to assess the efficacy of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) fixed-dose combination (FDC) in a Test and Treat model of care in newly diagnosed human immunodeficiency virus...

Added 1 year ago

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors...

Added 1 year ago

Search all clinical trials for HIV infection
 
Alastair Miller

I am a retired infectious disease physician with a particular interest in blood borne viruses (HIV/viral hepatitis), neurological infection and bone & joint infection. I now work part time in acute medicine and part time in medical training & education as deputy Medical Director of... Read more

What is Tropical Medicine?

At first sight this seems a question with an obvious response and not one that requires much debate in this blog. However, the answer may be more complex than it initially appears and may benefit from further exploration.